TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01137318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation and Parent Training
Description: Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive remediation and Parent Training
Description: Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
Study: NCT04622982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)
Description: Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) \<30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist.
Study: NCT03196479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and propofol mixture with 1:4 ratio
Description: K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
Study: NCT02965313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SSLS Procedure
Description: Synthetic suture repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BSSVF-M Procedure
Description: Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
Study: NCT02890160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firesorb
Description: Sirolimus Target Eluting Bioresorbable Vascular Scaffold

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE
Description: Everolimus Eluting Coronary Stent System
Study: NCT04043247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS without electrical stimulation
Description: Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
Study: NCT04210102

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung Ultrasound (LUS)
Description: Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung Ultrasound (LUS)
Description: Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs.
Study: NCT03036306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCX-001
Description: Nefopam cream formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCX-001
Description: Nefopam cream formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cream formulation without Nefopam
Study: NCT00982124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
Study: NCT04544540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Units of transfusion
Description: Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Units of transfusion
Description: Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
Study: NCT02809911

Intervention type: DEVICE
Group type: OTHER
Intervention: Provant

Intervention type: DEVICE
Group type: OTHER
Intervention: Provant
Study: NCT00589862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavix (Clopidogrel)
Description: 150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
Study: NCT04242394

Intervention type: PROCEDURE
Intervention: ERCP
Description: Routine ERCP procedures with gallbladder in situ patient

Intervention type: PROCEDURE
Intervention: ERCP
Description: Routine ERCP procedures with gallbladder in situ patient
Study: NCT02221479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor GZ316455
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study: NCT03057509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-DOTA-TOC
Description: Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens PET/MR scanner
Description: Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Siemens Software
Description: The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAR Octreotide
Description: LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
Study: NCT02710734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder tumor
Description: Performed at before and after AMVAC and after chemoradiation and intravesicle therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder tumor
Description: Performed at before and after AMVAC and after chemoradiation and intravesicle therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder tumor
Description: Performed at before and after AMVAC and after chemoradiation and intravesicle therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Intravenous on day 1 with radiation treatment
Study: NCT02055027

Intervention type: OTHER
Intervention: Comparison between groups
Description: Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence

Intervention type: OTHER
Intervention: Comparison between groups
Description: Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
Study: NCT01284322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
Study: NCT01142986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity care
Description: During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher reinforcement
Description: Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
Study: NCT00903461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR Antisense DNA
Description: * Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~* EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment.
Study: NCT02126371

Intervention type: DRUG
Group type: OTHER
Intervention: LEO32731
Study: NCT01270854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmalyte A
Description: Intravenous fluid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Intravenous fluid
Study: NCT04268589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality game
Description: routine
Study: NCT01439568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2510924
Description: Administered subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered intravenously
Study: NCT03500471

Intervention type: PROCEDURE
Intervention: Robotic-assisted Total Gastrectomy
Description: Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.

Intervention type: PROCEDURE
Intervention: Laparoscopic-assisted Total Gastrectomy
Description: Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Study: NCT03810339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
Study: NCT01323946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK1562902A
Description: Three intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK1562902A
Description: Three intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational vaccine GSK1562902A
Description: Three intramuscular injections
Study: NCT03300310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing visit
Description: nursing visit at patient home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no nursing visit
Description: the patient take his treatment without nursing visit
Study: NCT00003254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethynyluracil
Description: 10mg/m2/dose, PO, Days 1-28, q 5wk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
Study: NCT03525093

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: 5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: Participants receive a health education booklet on improving coping with stress.
Study: NCT03272516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy (MBCT)
Description: Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
Study: NCT04647071

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Garlic and onion concentrate
Description: Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Garlic and onion concentrate
Description: Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Microcrystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Microcrystalline cellulose
Study: NCT00600444

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venae sectio
Description: surgical preparation of the cephalic vene to insert a totally implantable access port.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punction of V. subclavia
Description: radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
Study: NCT04601922

Intervention type: OTHER
Intervention: Semi-structured interview
Description: The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways

Intervention type: OTHER
Intervention: Semi-structured interview
Description: The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways

Intervention type: OTHER
Intervention: Semi-structured interview
Description: The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways

Intervention type: OTHER
Intervention: Semi-structured interview
Description: The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
Study: NCT02193451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urodynamics
Description: Diagnostic test for urinary storage and voiding function

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT03711266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE-PC
Description: PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
Study: NCT03518723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-linear Periodized Resistance Training
Description: 8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: 8 week resistance training intervention, 3 sessions per week, 60 minutes per session
Study: NCT01475786

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose: 16 mg Engensis (VM202)
Description: Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose: 32 mg Engensis (VM202)
Description: Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)
Study: NCT04210102

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest radiography (CR)
Description: The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest radiography (CR)
Description: The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
Study: NCT01917370

Intervention type: PROCEDURE
Intervention: surgical treatment
Description: all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
Study: NCT01641055

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salmon protein hydrolysate
Description: 2.5g salmon protein hydrolysate per day for 8wk.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herring protein hydrolysate
Description: 2.5g herring protein hydrolysate per day for 8wk.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Cod protein
Description: 2.5g cod protein per day for 8wk.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk protein
Description: 2.5g milk protein per day for 8wk.
Study: NCT03366779

Intervention type: DEVICE
Group type: OTHER
Intervention: 6mm annular closure device
Description: 6MM Barricaid annular closure device implantation following standard lumbar discectomy
Study: NCT00853073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: balanced salt solution
Description: 0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
Study: NCT00935051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picture + MMPs and TIMP1 at week 0 and week 4
Description: Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
Study: NCT03519386

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: G2-TR intraocular implant containing travoprost
Description: Provided in Arm/Group descriptions.
Study: NCT01396876

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: clown
Description: a distraction technique is performed by a clown during venipuncture
Study: NCT01188993

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: early septic shock
Description: Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.